Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cybin ( (TSE:CYBN) ) has shared an update.
Cybin announced it will move its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market, with trading on NYSE American ending on January 4, 2026 and Nasdaq trading beginning January 5, 2026 under a new ticker symbol, HELP; its Cboe Canada listing will also adopt the HELP symbol on the same date. Management framed the switch as a key milestone in Cybin’s evolution into a global pharmaceutical player, positioning the mental-health-focused drug developer alongside larger peers on a more biotech-centric exchange, a move that could enhance visibility with investors focused on innovative healthcare and potentially support future capital-raising and strategic growth initiatives.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$48.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin Inc. is a clinical-stage pharmaceutical company focused on developing next-generation psychedelic-based therapies to transform mental healthcare. The company is advancing a pipeline that includes CYB003, now in Phase 3 trials as an adjunctive treatment for major depressive disorder with Breakthrough Therapy Designation from the U.S. FDA, and CYB004, in Phase 2 development for generalized anxiety disorder, alongside a broader portfolio of investigational compounds. Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom and Ireland, targeting large unmet needs in depression, anxiety and other mental health conditions.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.92M
For an in-depth examination of CYBN stock, go to TipRanks’ Overview page.